The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes.
Introduction
One of the two major types of Inflammatory Bowel Disease (IBD), known as Ulcerative Factor Alpha (Anti-TNF-α) as a biological treatment (12) .The biological therapy has changed therapeutic approaches to the inflammatory bowel diseases particularly in the case of refractory UC. Although their costs are higher, they work more quickly than traditional medicines in reducing symptoms [13] [14] [15] .
Infliximab was the first biologic treatment approved for treatment of adults with moderate to severe, which is unresponsive to conventional therapies [16] . Published researches indicated that that Infliximab is an effective treatment in these patients via achieving high clinical response rate, faster remission rate, and improving health related quality of life [16] [17] [18] .
It was found that infliximab reduced the need for surgery and hospitalization in severe acute and refractory UC patients [19] . However, in spite of demonstrated effectiveness of Infliximab in patients with UC, it is an expensive treatment option and sometimes not cost-effective. Also, some of recent economic evaluations showed that Infliximab maintenance treatment in moderate to severe UC patients is cost-effective [20, 21] .
To date, to best our knowledge, no study has ever examined the cost-effectiveness of infliximab in Refractory UC patients in Iran.
The present economic evaluation was performed to evaluate the costs, effects, and costeffectiveness of infliximab treatment compared with conventional treatments, in patients with moderate to severe UC.
Materials and Methods

Study Design
To assess cost-effectiveness of infliximab in UC patients, we developed a decision model with a 5-year-time horizon, to follow up 1000
hypothetical patients for estimating treatment costs and outcomes of infliximab compared with conventional treatments. Costs of treatment were estimated based on the local tariff and prices.
Clinical outcomes were obtained from available literature.
Conventional Treatment
Conventional treatment in UC patients is a medical treatment which is prescribed according to the severity and extent of disease. 
Clinical Outcome
UC is a chronic disease with recurrent inflammation [27] .The clinical course of UC is characterized by exacerbation and remission [28] . Almost 30% of patients need surgery [8] , but evidences showed that there is no difference in mortality rate between UC patients and general population [29] [30] [31] . Therefore, we Indirect costs are costs related to loss productivity caused by disease such as absent from work and premature retirement or death.
Due to the obstacles in measuring these costs, they are not included in this analysis.
As mentioned above, Infliximab is a weightbased drug with dosage of 5 mg/kg. In the case of weight-based dosing drug, patient's body weight is an important parameter which influences ICER value, and result is sensitive to it. In this study, in consultation with clinicians, patient's weight of 75 kg was used to estimate
Infliximab costs at dosage of 5 mg /kg. 
Model structure
Data Analysis Methods
The analysis took in the form of a cost- 
Results and Discussion
Clinical Efficacy
Outcomes-Health Status
The utility value for each health state, extracted from Arseneaus 'study conducted with time trade off method. The utility value for the remission, clinical response -active UC, and surgery outcomes were considered equal to 0.79, 0.32, and 0.68 respectively [32, 34] .
Measurement Costs
For this purpose, treatment costs related to conventional treatments and Infliximab were estimated for a one-year period, based on the approved tariffs in the public sector at 2014.
Conventional treatments include induction treatment (prednisone 1 mg/kg, azathioprine 50 mg, mesalazine 500 mg, methronidazol 250mg) and maintenance treatment (azathioprine 50 mg and mesalazine 250 mg).
Surgical procedures include total colectomy, partial colectomy, and ileal pouch anal anastomosis. Table 1 presents the resource and costs used in our model. According to the World Health Organization (WHO) guidelines for choosing cost -effective intervention, it is not cost -effective treatment option. It will be discussed as follow:
Cost -Utility Analysis
As we mentioned later, the aim of this analysis was to evaluate cost-effectiveness of infliximab treatment in refractory UC patients, compared with conventional treatments.
Although a meta-analysis of placebo-controlled trials showed that infliximab treatment is an effective strategy for these patients in terms of 
Healthcare use costs
Conclusion
We concluded that in comparison to conventional treatment, infliximab treatment is 
